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Micro-vascular and renal complications in diabetic patients
are a considerable clinical challenge. In a previous study, we
found a significant decrease in vascular endothelial growth
factor A (VEGF-A) mRNA levels in glomeruli from patients
with diabetic nephropathy (DN). We now set out to
investigate the relationship between reduced VEGF-A and
connective tissue growth factor (CTGF) expression levels, the
number of podocytes, and the extent of interstitial fibrosis.
Laser capture microdissection was applied to obtain
glomerular RNA from 28 patients with DN and 22 controls.
mRNA levels of VEGF-A, CTGF, nephrin, podocin, and Wilms
tumor1 (WT1) were measured using real-time polymerase
chain reaction. Protein expression was evaluated using
immuno-stainings for VEGF-A and CTGF, as well as markers
for podocytes (WT1) and endothelial cells (CD31). We found a
significant decrease in glomerular mRNA levels for VEGF-A
(2.5 times), CTGF (1.6), nephrin (2.8), podocin (3.3), and WT1
(1.7) in patients with DN. There was a significant correlation
between expression of podocyte markers and VEGF-A mRNA
levels, and an inverse correlation between podocin message
and the extent of interstitial fibrosis. CD31-positive area was
significantly decreased (3.2 times) in patients with DN.
Reduction of angiogenic factors correlated with the extent of
interstitial fibrosis. This downregulation was related to a
reduction of podocytes in DN. The results may suggest that
downregulation of VEGF-A and CTGF in DN is a result of
podocyte loss.
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Diabetic nephropathy (DN) is a major complication of both
type I and type II diabetes. It is the most common single
cause of end-stage renal disease.1,2 One of the earliest clinical
signs of DN is microalbuminuria, which may progress to
proteinuria3 and hyperfiltration followed by a decrease in the
glomerular filtration rate.
Morphologically, DN is characterized by glomerular
hypertrophy, expansion of the mesangial matrix, and
thickening of glomerular and tubular basement mem-
branes.4,5 In later stages of the disease, glomerulosclerosis
and interstitial fibrosis are prominent.
Although many factors, including high glucose, insulin,
advanced glycation end products , and high blood
pressure have been found to play a role in the initiation
and progression of DN, the precise molecular mechanisms
are still unclear. Several cytokines and growth factors
have been proposed to mediate the development of
DN. Transforming growth factor-b1 is the most widely
investigated molecule in relation to diabetic glomerulo-
sclerosis and interstitial fibrosis, most notably in animal
models.6
Vascular endothelial cell dysfunction is a common finding
in patients with type II diabetes mellitus.7 This may be related
to dysregulation of angiogenic factors, such as vascular
endothelial growth factor(VEGF-A). In diabetic retinopathy,
a condition that may lead to loss of vision, neovascularization
has been linked to increased expression of VEGF-A in non-
vascular cells of the retina.8 A role for VEGF-A in DN has also
been described. In streptozotocin (STZ)-induced diabetic
rats, treatment with monoclonal anti-VEGF antibodies
decreased hyperfiltration, albuminuria, and glomerular
hypertrophy.9 In contrast, another study reported that
VEGF is reduced in rat glomeruli 1 week after diabetes
induction with STZ.10 Studies in mice carrying one
hypomorphic VEGF-A allele and one podocyte-specific null
VEGF-A allele have shown that VEGF-A production by the
podocyte is critical for endothelial cell migration, survival,
proliferation, and differentiation within the glomerulus.11 In
human DN, it has been suggested that VEGF-A is important
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for maintaining glomerular endothelial cell function and that
a decrease in local VEGF-A levels accounts for abnormal
remodelling of the glomerular capillaries.12,13 Thus, endothe-
lial cell loss may be involved in the development of renal
disease and the progression to sclerosis. Apart from VEGF-A,
several other growth factors play a role in angiogenesis. For
example, connective tissue growth factor (CTGF) has been
shown to regulate invasive new vessel formation.14,15
Reduction of VEGF-A and CTGF may be a result of podocyte
loss, a phenomenon that has been described in DN.16,17
Despite recent progress in elucidating the role of perturbed
vascular biology in progressive renal disease, the role of
VEGF-A and CTGF in the pathogenesis of DN is still
unclear.18
In a previous study, using gene expression profiling we
identified a downregulation of several angiogenic factors in
isolated glomeruli of human kidneys with DN.12 Here, we
extend these results by studying the gene expression levels of
VEGF-A and CTGF in renal biopsies from patients with DN.
Using a combination of immunohistochemistry and quanti-
tative PCR, we quantified the number of podocytes and
endothelial cells and related this to the gene expression levels
of VEGF-A and CTGF. Correlations of expression levels with
clinical parameters and morphological changes were tested to
obtain further insight into the role of these molecules in the
development of DN.
RESULTS
Microarray experiments
In earlier gene expression profiling experiments on isolated
glomeruli from patients with DN, we found a significant
decrease in mRNA levels for VEGF-A and CTGF (19.5 and
6.5 times, respectively).12 To further expand the scope of
these investigations, we have performed oligonucleotide
microarray profiling of RNA isolated from the total
cortical part of kidneys from the same patients as those
described in the previous study. A total of six chips were
hybridized with RNA from three controls and three patients
with DN. Results of these experiments can be found in
qdetail at http://www-onderzoek.lumc.nl/pathology/kidney/
diabeticnephropathy/. Whole renal cortex mRNA levels of
VEGF-A (2.2 times) and CTGF (1.7 times) were decreased,
whereas expression of fibronectin (1.7 times) was increased in
patients with DN compared with controls.
Clinical parameters
Having identified transcripts as being differentially regulated
in DN using oligonucleotide microarrays, we validated their
mRNA levels in a large, independent group of 28 patients and
22 controls. Protein excretion and serum creatinine levels at
the time of biopsy for the patients with DN are depicted in
Figure 1. Serum creatinine levels ranged from 70 to
700 mmol/l (Figure 1a) and protein excretion ranged from
0.061 to 6.7 g/l (Figure 1b). There was no difference in age
(60.0710.9 years versus 61.6710.0 years) between diabetic
patients and controls.
Glomerular and whole cortical mRNA levels
VEGF-A mRNA levels in microdissected glomeruli as
measured by quantitative PCR were decreased 2.6. times
(Po0.01) in patients with DN compared with control
kidneys (Figure 2a). In whole renal cortex RNA, VEGF-A
mRNA levels in patients with DN were decreased 2.5 times
compared with controls (Po0.01) (Figure 2c). A similar
pattern of downregulation was observed for CTGF: glomeru-
lar and whole renal cortex mRNA levels for CTGF were 1.6
times decreased (Po0.05) in patients with DN (Figure 2b
and d). As expected, fibronectin mRNA levels were 2.8 and
1.9 times increased in glomerular and interstitial samples
from diabetic patients compared with controls (Po0.05 for
both comparisons).
The glomerular mRNA expression levels for the podocyte-
specific genes are shown in Figure 3. Nephrin, podocin, and
Wilms tumor1(WT1) were 2.8, 3.3, and 1.7 times decreased
in DN compared with controls (Po0.05, Figure 3a–c).
(Immuno)histochemistry
Interstitial fibrosis was quantified by morphometric analysis
on frozen sections stained with Sirius Red (Figure 4). There
was a significant increase in the extent of Sirius Red staining
in patients with DN compared with controls (33.3 versus
18.7%, Po0.01) (Figure 5a). CD31 (platelet-endothelial cell
adhesion molecule) staining was used as a marker for
endothelial cells. Both in the glomerular (Figure 5b) and
tubulo-interstitial compartment (Figure 5c), the CD31-
positive area in patients with DN was significantly decreased
compared with controls (7.0 versus 22.6% in glomeruli and
5.8 versus 9.9% in the tubulo-interstitium), suggesting a
reduction in the number of capillaries/endothelial cells in
DN. Representative pictures of these stainings are depicted in
Figure 4. To confirm the reduction of VEGF-A, CTGF, and
WT1 mRNA expression, we performed immunohistochem-
ical stainings for these proteins. VEGF-A staining of the
podocytes in the glomerulus was reduced in patients with DN
(Figure 6a and b). In control patients, CTGF showed staining
in the mesangium and among the glomerular capillary wall.
In diabetic patients, this staining largely disappeared.
Occasionally, positive cells were present in the mesangium
and in Bowman’s capsule (Figure 6c and d). Quantification of
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Figure 1 | Clinical characteristics of the diabetic patients.
(a) Serum creatinine levels (mmol/l) and (b) urine protein
excretion (g/l).
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WT1-positive nuclei showed a reduction of the number of
podocytes in biopsies from diabetic patients (16.276.2
versus 38.675.6 positive cell per glomerulus Po0.01)
(Figure 6e and f). There was a strong correlation between
the number of WT1-positive cells and the mRNA levels for
WT1 (R¼ 0.74, Po0.01) and the mean of the mRNA levels
for nephrin, podocin, and WT1 (R¼ 0.69, Po0.01).
Correlations
To identify statistically significant relationships between
variables, Pearson correlations were calculated between
clinical, (immuno)histochemical, and mRNA data. Results
of these correlations within the diabetic patient group are
summarized in Table 1. There was a positive correlation
between glomerular VEGF-A and CTGF mRNA levels
(R¼ 0.61, Po0.01). A negative correlation was found for
glomerular VEGF-A mRNA levels and Sirius Red-positive
area (R¼0.62, Po0.01). In other words, there was a
relationship between reduction of glomerular VEGF-A
mRNA levels and the amount of interstitial fibrosis as a
marker for progression of DN. Glomerular mRNA levels for
VEGF-A also correlated with glomerular nephrin (R¼ 0.57,
Po0.01), podocin (R¼ 0.72, Po0.01), WT1 (R¼ 0.53,
Po0.01), and the mean of these podocyte-specific
(R¼ 0.673, Po0.01) mRNA levels. Glomerular mRNA levels
for CTGF correlated with glomerular nephrin (R¼ 0.49,
Po0.05), podocin (R¼ 0.56, Po0.01), WT1 (R¼ 0.67,
Po0.01), and the mean of these podocyte-specific
(R¼ 0.731, Po0.01) mRNA levels. Whole renal cortex
mRNA measurements showed correlations between VEGF-
A and glomerular CD31 (R¼ 0.531, Po0.01). Podocin
mRNA levels correlated with those of nephrin (R¼ 0.43,
Po0.05) and WT1 (R¼ 0.62, Po0.01).
When evaluating all samples together (controls and DN),
a significant correlation was found between glomerular
VEGF-A and the CD31-positive area, both for the glomerular
(R¼ 0.50, Po0.01) and the tubulo-interstitial compartments
(R¼ 0.42, Po0.01). We also found a correlation between the
Sirius Red-positive area and serum creatinine levels
(R¼ 0.411, Po0.01) and proteinuria (R¼ 0.593, Po0.01),
and between the glomerular CD31-positive area and the
mean of podocyte-specific mRNA levels (R¼ 0.425,
Po0.01). There was a negative correlation between Sirius
Red staining and both glomerular and interstitial CD31
staining (R¼0.654, Po0.01 and R¼0.451, Po0.01,
respectively).
DISCUSSION
In this study, we analyzed the angiogenic factors, VEGF-A
and CTGF, in renal biopsies from patients with DN and
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Figure 2 | Box and whisker plots of mRNA levels for VEGF-A and CTGF. The boxes contain 50% of the values. The upper and lower border
indicate the 25th and the 75th percentile. The upper and lower whisker indicate the highest and lowest value. The black line in the box
indicates the median and open circles indicate outliers. (a) Relative mRNA levels for glomerular VEGF-A (Po0.01), (b) glomerular CTGF
(Po0.05), (c) interstitial VEGF-A (Po0.01), (d) interstitial CTGF (Po0.05).
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healthy controls. We found a downregulation for glomerular
VEGF-A and CTGF mRNA levels. This downregulation was
correlated with reduction of podocytes and the progression
of renal disease.
The genes measured in this study were identified using
microarray analysis of glomerular and tubulo-interstitial
mRNA from diabetes patients with DN and healthy controls.
Differentially expressed transcripts included several genes
that play a role in endothelial cell maintenance and
angiogenesis. To explore the implications of these gene
expression alterations, a number of these genes were further
investigated in a larger group of patients with different stages
of DN.
VEGF-A is one of the most important angiogenic growth
factors regulating vasculogenesis and permeability of endo-
thelial cells.19 Our results show decreased VEGF-A mRNA
levels in patients with DN. Bailey et al.20 found a decrease in
VEGF-A mRNA in glomeruli from patients with DN using in
situ hybridization. These results were confirmed by others in
both the interstitial21 and the glomerular compartments.13 In
addition, a negative correlation was found between glomeru-
lar VEGF-A levels and proteinuria.21 Results from animal
studies on the action of VEGF-A are contradictory. In STZ-
induced diabetic rats, treatment with anti-VEGF-A anti-
bodies decreased hyperfiltration, albuminuria, and glomeru-
lar hypertrophy.22 Tumstatin peptide, an inhibitor of
angiogenesis, suppressed glomerular matrix expansion, the
development of albuminuria, and renal mRNA expression of
VEGF-A in STZ-induced diabetic mice.23 In contrast,
another study report that glomerular expression of VEGF-A
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Figure 3 | Box and whisker plots of mRNA levels for nephrin,
podocin and WT1. (a) Relative glomerular mRNA levels for nephrin
(Po0.01), (b) podocin (Po0.01), and WT1 (c) (Po0.05). The black line
in the box indicates the median and open circles indicate outliers.
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Figure 4 | Sirius Red and CD31 staining in the biopsies.
(a and b) Illustrations of the Sirius Red staining in a control patient
and in a patient with DN, respectively. (c–f) Pictures of CD31
staining: glomerulus of a control patient (c), glomerulus of a
patient with DN (d), the tubulo-interstitial part of a control patient
(e), and (f) the tubulo-interstitial part of a diabetic patient.
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is reduced 1 week after STZ induction.10 This reduction
could be restored by treatment of the rats with insulin.10
Decreased VEGF-A expression was recently documented in
the remnant kidney model, and treatment of these animals
with VEGF-A reduces renal fibrosis.24 Studies in mice show
that glomerular-selective depletion or overexpression of
VEGF-A leads to glomerular abnormalities.25,26
It is known from other studies that CTGF plays a role in
angiogenesis,14,15 suggesting that, similar to VEGF-A, CTGF
in the podocyte may be involved in endothelial maintenance.
In our study, CTGF mRNA expression levels were down-
regulated in both the glomerular and tubulo-interstitial
compartments of the diabetic kidney. These results are
contradictory to those from a number of other studies that
found increased CTGF levels in DN.27–30 However, some of
these data represented the number of mRNA molecules per
glomerulus whereas our data represent relative steady-state
mRNA levels corrected for three different housekeeping
genes. Another reason for the differences between our
findings and those reported in the literature may be that
the stage of the disease studied is different. Animal models
are often studied in an early phase of the disease, whereas
most of our patients were already in a moderate to severe
stage of the disease. In patient studies, it is difficult to receive
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Figure 5 | Box and whisker plots of Sirius Red and CD31 staining
in the biopsies. The extent of interstitial fibrosis measured as the
percentage of the interstitial Sirius Red-positive area in the renal
cortex. (a) Diabetic patients showed significantly more fibrosis than
controls (Po0.01). (b) Percentage of glomerular CD31 staining.
Percentage of tubulo-interstitial CD31 staining. (c) The percentage
of CD31-positive area in both the glomerular and tubulo-interstitial
compartments in patients with DN were significantly decreased
compared with controls (Po 0.01).
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Figure 6 | VEGF-A, CTGF, and WT1 staining in the biopsies.
(a and b) Illustrations of the staining for VEGF-A in a control (a) and
(b) in a patient with DN. VEGF-A staining of the podocytes in the
glomerulus is reduced in patients with diabetes. (c and d) Pictures
of CTGF staining. (c) CTGF showed mesangial staining and
staining among the glomerular capillary wall in control patients.
(d) In glomeruli of diabetic patients, this staining had disappeared.
Sometimes, a positive cell could be found in the mesangium
(arrowhead) and in Bowman’s capsule (e, and f show a representative
picture of WT1 staining of (e) a control and (f) a DN sample.
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biopsy material at an early stage of disease, as patients do not
normally present to a nephrologist until the disease has
become manifest. It is also likely that mechanisms for
initiation and progression of DN in animals differ from those
seen in humans.31
Because of the fact that all genes measured in our
study were downregulated, we measured fibronectin
mRNA. Fibronectin is one of the major extracellular matrix
proteins present in glomerulosclerotic and interstitial fibrotic
lesions, which was upregulated from our microarray experi-
ments. As expected, fibronectin mRNA levels showed an
increase in patients with DN compared with controls,
indicating an ongoing process of glomerular and interstitial
fibrogenesis.
As histological grading of tubulo-interstitial fibrosis is
closely correlated with the loss of renal function,32 quanti-
tative measurements of the Sirius Red staining were used as a
morphological marker for disease progression. We found a
significant increase in the extent of Sirius Red staining in
patients with DN compared with controls. The observation
that glomerular VEGF-A mRNA levels negatively correlated
with the extent of Sirius Red staining supports the concept
that loss of VEGF-A is related to progression of DN. This was
already suggested by Bortoloso et al.13 who found a negative
correlation between VEGF-A levels and urinary protein
excretion.
The question remains by what mechanism VEGF-A and
CTGF are downregulated in DN. One explanation may be
that specific downregulation occurs in a diabetic milieu. This
is unlikely as cell culture experiments have shown that
glucose, insulin, and advanced glycated end products increase
levels of VEGF-A and CTGF.33–36 It is more likely that the
decrease in expression of angiogenic factors, normally
produced by podocytes, results from podocyte loss. It has
been shown that the number of podocytes decreases over the
course of DN.16,17 Podocyte loss can be the result of high
glucose levels,37 raised insulin levels,38 or hypertension.39 In
this study, we found a decrease in the mRNA expression of
the podocyte-specific genes nephrin, podocin, and WT1. The
expression of these genes showed a strong correlation with
the number of podocytes as measured by WT1 staining. This
suggests that the synchronous decrease in expression of these
molecules can be used as a marker of podocyte loss. There
was a high correlation of VEGF and CTGF expression levels
with the expression of podocyte-specific genes and the
number of podocytes. Taken together, this suggests that the
observed decreases in angiogenic factors result from the loss
of podocytes. From the results of this study, we speculate that
loss of angiogenic factors contributes to the progression of
DN. Podocyte loss leads to a reduction in expression of
angiogenic factors, which are necessary for the normal
maintenance of the endothelial cells. Indeed, injured
podocytes are ineffective in mediating glomerular endothelial
angiogenesis, proliferation, and migration, as a result of
decreased VEGF-A and Ang-1.40 The reduced endothelial cell
maintenance in combination with endothelial cell dysfunc-
tion leads to a loss of endothelial cells. This endothelial cell
loss may lead to thrombotic microangiopathy followed by
loss of capillaries. Development of the latter has been shown
by fragmented red blood cells and PAI-1, a marker for
progression of thrombosis to sclerosis, in glomeruli from
diabetic patients with severe nodular lesions.41 Taken
together, these findings are consistent with a model in
which the endothelial cell defects result from direct
endothelial damage as a result of diabetic factors and
rom podocyte loss leading to diminished production of
pro-angiogenic factors.
In conclusion, this study demonstrates a reduction in
mRNA levels of angiogenic factors in glomerular and whole
kidney mRNA samples from renal biopsies of patients
suffering from type II diabetes-induced DN. Reduction of
angiogenic factors correlated with the extent of interstitial
fibrosis and a reduction of podocytes. We also found a
reduction of glomerular and interstitial endothelial cells in
DN. The results may suggest an important role for angiogenic
factors in the maintenance of endothelial cells. Reduced
expression of angiogenic factors may be involved in the
progression of DN.
MATERIALS AND METHODS
Array studies on diabetic kidneys
We extended our previously reported gene expression profiling on
isolated glomeruli from diabetic kidneys12 by profiling whole
cortical RNA. Kidneys from deceased donors were obtained from
Eurotransplant. These kidneys were unsuitable for transplantation
owing to technical or morphological reasons.12 Three control
kidneys and three kidneys from patients with DN were used. Clinical
information about these patients is listed in Table 2. Hybridizations
were performed on the Human Genome U95Av2 Array (Affymetrix,
Santa Clara, CA, USA). Ten micrograms of total cortical RNA was
converted to complementary DNA, double stranded DNA, and
transcribed in vitro according to the instructions of the manufac-
turer. After hybridization, the microchips were scanned and
analyzed with Affymetrix Microarray Suite 5.0 software. Statistics
of this method are available at http://www.affymetrix.com/support/
technical/manuals.affx.
To identify which genes of expression was altered consistently
in the disease samples, we used either those genes that were
present on all six chips or those present in all three control
samples but absent in all three diabetic samples, or vice versa.
We employed multiple pair-wise comparisons between control
and disease groups using the OpenStat statistics package (Student’s
t-test, Po0.01).
Renal biopsies
To confirm and extend the results of the array experiments, we
selected frozen biopsies from patients with DN (n¼ 28) from the
pathology archive of the Leiden University Medical Center and the
Institute for Clinical Pathology, Heidelberg. All patients had type II
diabetes. DN was histologically confirmed in periodic acid-schiff
stained paraffin sections. Criteria for DN included glomerular
hypertrophy, diffuse mesangial and focal nodular glomerulosclero-
sis, arteriolar hyalinosis, focal and segmental glomerulosclerosis, the
presence of hyaline drops between Bowman’s capsule and epithelial
cells, and interstitial fibrosis. Serum creatinine levels and albumi-
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nuria of the patients are depicted in Figure 1. As a control group
(n¼ 22), we used native kidneys with normal function and histology
obtained at autopsy (n¼ 3), cadaver donor kidneys unsuitable for
transplantation for technical reasons (n¼ 7), and the non-affected
part of tumor nephrectomy samples (n¼ 12). Clinical information
about diabetic patients and controls is available on our website (http://
www-onderzoek.lumc.nl/pathology/kidney/diabeticnephropathy/). There
were no significant differences between the different control groups
Table 1 | Bivahiate Pearson correlations among mRNA levels, serum creatinine, proteinuria, Sirius Red and CD31-positive area
within the diabetic patient group
Glomerular mRNA level Glomerular Interstitial Interstitial mRNA level
Proteinuria VEGF-A CTGF Nephrin Podocin WT1 Meana CD31 Sirius Red CD 31 VEGF-A CTGF
Serum creat. Correlation (R) 1.000
P-value
Proteinuria Correlation (R) 0.462 1.000
P-value 0.030b
Glomerular VEGF-A Correlation (R) 0.066 0.011 1.000
mRNA P-value 0.765 0.963
Level CTGF Correlation (R) 0.220 0.089 0.611 1.000
P-value 0.301 0.709 0.000c .
Nephrin Correlation (R) 0.154 0.098 0.508 0.487 1.000
P-value 0.482 0.681 0.009c 0.013b
Podocin Correlation (R) 0.002 0.125 0.722 0.557 0.431 1.000
P-value 0.993 0.598 0.000c 0.006c 0.040b
WT1 Correlation (R) 0.086 0.420 0.530 0.666 0.261 0.613 1.000
P-value 0.705 0.065 0.007c 0.000c 0.218 0.002c
Meana Correlation (R) 0.062 0.272 0.673 0.731 0.555 0.862 0.892 1.000
P-value 0.774 0.209 0.000c 0.000c 0.004c 0.000c 0.000c
Glomerular CD31 Correlation (R) 0.265 0.149 0.327 0.134 0.234 0.340 0.219 0.033 1.000
P-value 0.222 0.541 0.119 0.522 0.282 0.131 0.328 0.878
Interstitial Sirius Red Correlation (R) 0.191 0.287 0.618 0.255 0.129 0.571 0.228 0.410 0.455 1.000
P-value 0.383 0.234 0.001c 0.219 0.558 0.007c 0.308 0.046b 0.019 .
CD 31 Correlation (R) 0.472 0.334 0.021 0.256 0.040 0.048 0.422 .354 0.675 0.123 1.000
P-value 0.019b 0.150 0.923 0.217 0.854 0.832 0.045b 0.082 0.000c 0.548
Interstitial VEGF-A Correlation (R) 0.223 0.259 0.328 0.196 0.073 0.075 0.224 0.072 0.531 0.233 0.201 1.000
mRNA P-value 0.274 0.245 0.102 0.328 0.723 0.727 0.281 0.720 0.004c 0.251 0.304
Level CTGF Correlation (R) 0.007 0.443 0.135 0.263 0.266 0.197 0.325 0.003 0.044 0.022 0.223 0.095 1.000
P-value 0.974 0.044b 0.521 0.194 0.198 0.367 0.121 0.989 0.831 0.916 0.263 0.598
CTGF, connective tissue growth factor; VEGF, vascular endothelial growth factor; WT1, wilms tumor 1.
Correlation coefficients (R) and P-values are given.
aMean of podocyte specific mRNA level (nephrin, podocin, and WT1).
bCorrelation is significant at the 0.05 level (two-tailed).
cCorrelation is significant at the 0.01 level (two-tailed).
Table 2 | Characteristics of the patients used for microarray experiments
Control 1 Control 2 Control 3 Diabetes 1 Diabetes 2 Diabetes 3
Retinopathy No No No Yes Yes unknown
Duration of diabetes type II (years) — — — 45 45 45
Age (years) 29 70 74 55 63 62
Gender Male Male Female Male Male Male
Serum creatinine (mg/dl)a 0.68 Unknown 1.0 1.14 Unknown 0.99
Serum Glucose (mg/dl)a 133 128 144 326 Unknown 322
Urine glucose (g/l)a Negative Negative Unknown 4.3 ++
Urine protein (g/l)a Negative Trace Negative 1.54 +/ 0.44
GFR (ml/min)a 181 Unknown Unknown 78 Unknown 98
Perfusion fluid UWb UWb UWb UWb UWb UWb
Cold ischemia time (h) 32 33 27 26 32 30
Dopamine (mg/kg BW/min) 3 0.2 (norepinephrine) 3 2 3 5 (Dobutrex)
Known other drugs — — Insulin Insulin Azacton
Cause of death ICB ICB ICB ICB ICB SBT
Reason of refusal Lesion upper
arterial pole
Arteriosclerosis Arteriosclerosis Diabetic
nephropathy
Diabetic
nephropathy
Diabetic
nephropathy/
arteriosclerosis
Percentage of sclerotic glomeruli o1% o1% o1% 33% 24% 7%
Percentage of interstitial fibrotic area o5% o5% o5% 25–50% 25–50% 5–10%
GFR, growth factor receptor; ICB, intracerebral bleeding; SKB skull/brain trauma.
aLevels within last 24 hours of donation.
bUniversity of Wisconsin solution.
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for any of the parameters measured. Patient studies were approved
by the Institutional Ethical Committee.
Microdissection and RNA isolation from glomeruli
The PALM Laser-MicroBeam System (Wolfratshausen, Germany)
was used for microdissection of glomeruli from renal biopsies
according to the method of Specht et al.42 In brief, three 4 mm
cryosections were put on a polyethylene foil-coated slide. After
selecting the glomeruli (2075 glomeruli from each biopsy), they
were dissected with a laser beam and catapulted into a reaction tube
containing RLT buffer (RNeasy kit, Qiagen GmbH, Germany). RNA
was isolated from these glomeruli with Trizol, according to the
manufacturer’s instructions.
RNA isolation from renal cortex
Cryostat sections were cut from each biopsy. The presence of
cortex was confirmed by light-microscopic localization of glomeruli
in the sections. Ten 10 mm sections were cut and collected in a
reaction tube. RNA was isolated using RNeasy Mini columns
(Qiagen GmbH, Germany), according to the manufacturer’s
instructions.
cDNA synthesis
RNA from microdissected glomeruli and whole cortex was
converted to cDNA using avian myeloblastosis virus reverse
transcriptase (Roche Applied Science, Almere, The Netherlands) in
combination with oligo-dT and random hexamer priming. RNA
without reverse transcriptase was used as negative control.
Quantitative real-time PCR
Quantitative real-time PCR43 was used in combination with
Taqman probes to quantify the gene transcription levels for
VEGF-A and CTGF. The primer/probe combination for VEGF
detects all isoforms of VEGF-A. Glomerular gene transcription levels
for podocin, nephrin, and WT1 were measured. The mean of these
three podocyte-specific genes was used as a measure for the number
of podocytes. Primer and probe sequences are listed in Table 3.
Details concerning the quantitative PCR protocol have been
described elsewhere.44 The transcription levels of the genes of
interest were determined and corrected to a panel of three
housekeeping genes, that is, glyceraldehyde-phosphate-dehydrogen-
ase, hypoxanthine phosphoribosyl transferase, and TATA box-
binding protein, as described by Vandesompele et al.45 These
housekeeping genes were selected from a panel of five different
housekeeping genes46 on the basis of the highest correlations
between each other (RX0.85). The relative values of each of the
three different housekeeping genes of the controls were adjusted to
one by dividing the samples by the mean of all samples. After this
correction, the mean of the three different housekeeping genes was
calculated. The relative expression levels of the genes of interest were
obtained by dividing the value of the gene by the mean of the
different housekeeping genes. The relative values of the controls
were set to one.
(Immuno)histochemistry
Sirius Red staining was used to quantify the amount of interstitial
fibrosis47 as a marker for progression of renal disease.48,49 IHC
stainings were performed for VEGF-A, CTGF, endothelial cells
(CD31), and podocytes (WT1). In brief, the slides were washed in
phosphate-buffered saline and incubated for 2 h at room tempera-
ture with the primary antibody (rabbit anti-CD31 (Dako, Glostrup,
Denmark) anti-WT1, anti-VEGF, and anti-CTGF (Abcam plc,
Cambridge, UK). After washing with phosphate-buffered saline,
the slides were incubated for 30 min with horseradish peroxidase
conjugated anti-rabbit Envision (Dako, Glostrup, Denmark), and
the staining was developed with diaminobenzidine. The color was
enhanced by rinsing the slides in 0.5% CuSO4 solution for 5 min.
After counterstaining with hematoxylin, the slides were dehydrated
and mounted. To avoid inter-assay variation, all sections were
stained in one session.
Digital image analysis
Digital image analysis was performed using a Zeiss microscope
equipped with a full-color 3CCD camera (Sony DXC 950p) and KS-
400 image analysis software version 3.0. (Zeiss-Kontron, Eching,
Germany). Images of all glomeruli (3–15) present in the slides were
taken and the percentage of the area stained for CD31 was calculated
and used as a measure for the number of endothelial cells. To
quantify the number of podocytes, the number of WT1-positive
nuclei per glomerulus was counted in 15 representative biopsies. In
10 adjacent microscopic fields of renal cortex, the percentage of
Sirius Red-positive area was quantified as a measure of interstitial
fibrosis.
Statistics
Statistical analysis for comparison of mRNA expression, Sirius Red-
stained area, and CD31-stained area between groups was performed
using independent Student’s t-test. Pearson correlations were
calculated using SPSS 10.0.1 software. Po0.05 were considered
significant.
Table 3 | Primer and Taqman probes sequences
Forward primer Reverse primer Taqmans probe
VEGF-A AAACCCTGAGGGAGGCTCC TACTTGCAGATGTGACAAGCCG CCTCCTGCCCGGCTCACCGC
CTGF GGAAGAGAACATTAAGAAGGGCAA CTCGGTATGTCTTCATGCTGGTG CGTACTCCCAAAATCTCCAAGCCTATCA
Fibronectin GGAGAATTCAAGTGTGACCCTCA TGCCACTGTTCTCCTACGTGG AGGCAACGTGTTACGATGATGGGAAGACAT
WT1 GCCAGCCCGCTATTCGCAATC GCTTGAATGAGTGGTTGGGGAACTG SYBRs green
Podocin GGCTGTGGAGGCTGAAGC CTCAGAAGCAGCCTTTTCCG SYBRs green
Nephrin AGGACCGAGTCAGGAACGAAT CTGTGAAACCTCGGGAATAAGACA TCAGAGCTCCACGGTCAGCACAACAG
GAPDH TTCCAGGAGCGAGATCCCT CACCCATGACGAACATGGG CCCAGCCTTCTCCATGGTGGTGAA
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT CTTGACCATCTTTGGATTATACTGCCTGACCA
TBP CACGAACCACGGCACTGATT TTTTCTTGCTGCCAGTCTGGAC TGTGCACAGGAGCCAAGAGTGAAGA
CTGF, connective tissue growth factor; GAPDH, glyceraldehydes-phosphate-dehydrogenase; HPRT, hypoxanthine phosphoribosyl transferase; TBP, Tata box-binding protein;
VEGF, vascular endothelial growth factor; WT1, Wilms tumor 1.
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